Abstract:Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL The ERBB2 receptor tyrosine kinase gene is frequently amplified and mutated in human cancer. However, mutations characterized to date have been located in the kinase domain of the receptor. Using publically-available sequencing datasets, we have found that extracellular domain mutations of ERBB2 located beneath the dimerization arm recur in lung, breast, and ovarian cancers. We expressed cDNAs harboring these mutations in NIH-3T3 cells and found that the mutants support anchorage-independent proliferation. We furthermore found that substitution of any one of a number of amino acids in this region of the protein is oncogenic. We sought to biochemically characterize the extracellular domain mutations of ERBB2 and found that they cause oncogenic transformation by one of two mechanisms: elevation of C-terminal tail phosphorylation, or reduction-sensitive covalent dimerization unaccompanied by increases in C-terminal phosphorylation. Analysis of tyrosine phosphorylated proteins in the cell by stable isotope labeling followed by mass spectrometry (SILAC) revealed that both classes of mutant receptor phosphorylated the same set of proteins to effect transformation. The most prominent targets were proteins involved in cytoskeletal and membrane dynamics, controlling cell motility. STAT3 was also phosphorylated to a limited extent in ERBB2-transformed cells. Interestingly, STAT3 phosphorylation was mediated solely by a JAK-dependent autocrine loop in cells transformed by the ERBB2 mutants activated by reduction-sensitive dimerization; whereas both ERBB2 and JAK family kinases contributed to STAT3 phosphorylation in cells transformed by ERBB2 mutants exhibiting increased C-terminal phosphorylation. In order to characterize inhibitor sensitivity, we transformed Ba/F3 cells to IL-3 independence with the ERBB2 extracellular domain mutants. All extracellular domain mutants tested were sensitive to irreversible inhibitors of ERBB2, suggesting that treatment with such inhibitors may benefit patients harboring mutations of the extracellular domain of ERBB2. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1. doi:1538-7445.AM2012-1

Structural and dynamic characterization of the C-terminal tail of ErbB2: Disordered but not random

Expanding the Disorder-Function Paradigm in the C-Terminal Tails of Erbbs

Molecular Architecture of the Erbb2 Extracellular Domain Homodimer

Modeling Time-Dependent Transcription Effects Of Her2 Oncogene And Discovery Of A Role For E2f2 In Breast Cancer Cell-Matrix Adhesion

DEPTOR Stabilizes ErbB2 to Promote the Proliferation and Survival of ErbB2-positive Breast Cancer Cells.

Structure and dynamics of the EGFR/HER2 heterodimer

Oncogenic Extracellular Domain Mutations Of Erbb2 In Cancer

Structural Analysis of the EGFR TK Domain and Potential Implications for EGFR Targeted Therapy

De novo design of ErbB2 epitope targeting fusion protein stabilized by coiled coil structure.

Functional Analysis of Receptor Tyrosine Kinase Mutations in Lung Cancer Identifies Oncogenic Extracellular Domain Mutations of Erbb2

Comprehensive Functional Analysis of the Tousled-Like Kinase 2 Frequently Amplified in Aggressive Luminal Breast Cancers

ERBB2 comprehensive profiling and prognostication in Stage III Colon Cancer: Findings from PETACC8 and IDEA-France cohorts

Role of Erbin in Erbb2-Dependent Breast Tumor Growth

EGF–ERBB signalling: towards the systems level

Emerging paradigms and recent progress in targeting ErbB in cancers

Distinct ErbB-2 coupled signaling pathways promote mammary tumors with unique pathologic and transcriptional profiles

Investigations of EGFR configurations on tumor cell surface by high-resolution electron microscopy

Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes

Erbin interacts with NHERF1 and Ezrin to stabilize a membrane ErbB2 signaling complex in HER2-positive breast cancer

Structural insights into characterizing binding sites in EGFR kinase mutants

Mutational Analysis of ErbB2 Intracellular Localization.